Proactive Investors - Run By Investors For Investors

Polarean Imaging to receive third tranche of research grant

The grant was awarded from the National Heart, Lung and Blood Institute to Polarean and Cincinnati Children's Hospital Center. The money will continue to fund an ongoing Phase III trial evaluating the use of 129 Xe MRI scanning on children suffering from cystic fibrosis.
Cystic fibrosis patient
In the US alone, there are currently over 30,000 people with cystic fibrosis

Polarean Imaging PLC (LON:POLX), the medical imaging technology company, is set to receive another US$1mln through a research grant.

The company said it will receive the third tranche of US$1mln as part of its US$3mln Small Business Innovation Research grant.

READ Polarean adds third trial site to late-stage study of its lung MRI scan technology

The funds will be used to continue a Phase III trial evaluating the use of 129 Xe magnetic resonance imaging scanning for children being treated for cystic fibrosis (CF).

"Year three of this NIH [US National Institutes of Health] proposal will allow us to fully validate the hypothesis that hyperpolarised Xe MRI is sensitive to mild lung-function declines associated with CF in children. We anticipate that this work programme will be a launching point for future studies that will use the technique as a primary or secondary endpoint to demonstrate efficacy of therapeutic agents in CF and other obstructive lung diseases,” said Jason Woods of the Cincinnati Children’s Hospital Medical Center – one of Polarean’s long-standing collaborators.

Richard Hullihen, the chief executive officer of Polarean, said there are several new drug therapies under development by manufacturers and a key element in expediting the development and commercialisation process is having quantitative, reproducible, non-invasive imaging-based measures of a biological state (i.e. biomarkers).

“These biomarkers could reduce the cost of trials and maximise the outcome and proof of cost efficacy in this critical patient population. Achieving these milestones may facilitate expansion of the developed techniques to other members of the Xenon MRI Trials Consortium for multi-centre trials. We believe the applications being developed in CF could further expand the use of 129-Xe imaging as we continue to progress our own Phase III Clinical Trials, which are testing our drug-device combination for the evaluation of pulmonary ventilation," Hullihen said.

Shares in Polarean were up 2.4% at 16.125p in early trading.


 

View full POLX profile View Profile

Polarean Imaging PLC Timeline

Related Articles

CEO at CEO Session
Fri
The company provides a software as a service (SaaS) platform for social media marketing.
An armour plate based on XTclave technology
April 28 2019
The upper limit of the defence supplier’s guidance this half-year is $21.6 million.
plasma torch
May 03 2019
PyroGenesis harnesses the unique properties of thermal plasma to melt and transform metal, carry out high temperature chemical reactions and convert waste into energy

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use